RETA GLP-3Explore study findings
Why TRIUMPH-2 enrolled adults with type 2 diabetes
2 numbered sourcesSource years 2026
Peptides are short chains of amino acids linked by peptide bonds. Some influence the body’s response to nutrients by engaging receptors. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight. [1]
The investigators enrolled adults at 92 centers in eight countries. Participants had type 2 diabetes and were already on stable diabetes management. Most were using an oral glucose-lowering medicine at the start. The researchers randomized 1,152 people to one of three retatrutide groups or placebo. In this setting, the comparison includes the role of that stable background care. A trial that enrolled only people whose diabetes was managed with lifestyle measures would have a different starting population. [1]
The primary comparison looked at the percentage change in body weight from baseline to week 80 in two retatrutide groups versus placebo. Under the analysis that reflected treatment assignment, estimated average changes were −16.8% and −18.8% for the two main active groups and −5.1% for placebo. The third active group had an estimated average change of −11.9%. The study also reported blood sugar measures and safety outcomes. Group assignment, adherence and missing measurements all help determine what a trial estimate means. The report explains how missing data were estimated for the primary analysis. [1]
About 84% of randomized participants completed treatment with the study drug. A result based on assignment gives a broader view than an average calculated only for people who finished treatment exactly as planned. The study still describes a population that was eligible for this protocol and followed in a controlled setting. People with different diabetes histories or treatments could have different responses, and clinical decisions require more than the group average. [1]
The separate TRIUMPH-1 trial focused on people without diabetes. Its results can be read beside TRIUMPH-2 to learn about the populations the research program examined. A difference between reported percentages across the two trials cannot isolate the effect of having diabetes, because participants were randomized within each trial and not across the two populations. TRIUMPH-2 provides the randomized comparison of retatrutide and placebo for its enrolled adults with type 2 diabetes. The approval status remains a separate question from this trial’s results. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
